Review



lenvatinib experiment  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    MedChemExpress lenvatinib experiment
    CD73 is a key mediator of the HOXD13-dependent T-cell exclusion phenotype. A, The NT5E locus displays different regulatory elements contacting each other and bound by HOXD13. Silencing of HOXD13 reduces the contacts around the NT5E promoter. B, Bar dot plot representing CD73 protein quantification in tumor (left) and blood vessel (right) areas of a TMA in which cores were segregated into HOXD13 -expressing ( n = 61) and HOXD13 -negative ( n = 39). An unpaired t test was conducted, and P values are displayed. C, Representative HOXD13 low and HOXD13 high cores (RNAScope, top) and CD73, SOX10, and CD31/CD34 (mIF, bottom). The white scale bar measures 200 μm. D, qRT-PCR of Nt5e (Cd73) mRNA expression in B16F10 OVA cells that are EMPTY or Cd73 overexpressing, incubated with siSCR or siHoxd13. A paired t test was performed, and P values are shown in the graphs. E, Relative cell growth of B16F10 OVA carrying Cd73 ectopic expression cocultured with OT-I T cells upon Hoxd13 KD. A two-way ANOVA was conducted between the conditions. P values are shown. F, YUMM1.7 EMPTY or HOXD13 OE tumor growth expressing an shSCR (control) or shCd73. Mixed-effect analysis with Tukey comparison was conducted. The P value of the comparison YUMM1.7 HOXD13 shSCR vs. shCd73 is displayed. G, Tumor growth measurements of YUMM1.7 HOXD13 syngeneic grafts upon vehicle (control), <t>lenvatinib,</t> etrumadenant, or lenvatinib + etrumadenant (combo). Mixed-effects analysis through Tukey multiple comparison was performed, and P values are shown in the curves’ graph. H, Representative mIF staining for DAPI, CD45, CD3, CD11b, CD31, and α-SMA in YUMM1.7 HOXD13 tumors upon vehicle, etrumadenant, lenvatinib, and combo treatments. Combo dramatically decreased intratumor vasculature (CD31, α-SMA) and increased immune cells, particularly macrophage infiltration (CD45, CD11b). White bars reflect 500 mm size. I, B16F10 tumor growth in syngeneic mice upon shNTC, shHoxd13, or treated with vehicle or combo ( n = 9 mice per condition). Mixed-effect Tukey comparison was used as a statistical study; P values are shown. J, mIF opal staining for fibrin, α-SMA, and CD31 in representative tumor areas of B16F10 tumors shNTC, shHoxd13, vehicle, and combo treated. The scale bar is a reference of 50 μm.
    Lenvatinib Experiment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 140 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenvatinib+experiment/Lenvatinib/pmc13223554-372-4-49
    Average 97 stars, based on 140 article reviews
    lenvatinib experiment - by Bioz Stars, 2026-10
    97/100 stars

    Images

    1) Product Images from "A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma"

    Article Title: A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma

    Journal: Cancer Discovery

    doi: 10.1158/2159-8290.CD-24-1853

    CD73 is a key mediator of the HOXD13-dependent T-cell exclusion phenotype. A, The NT5E locus displays different regulatory elements contacting each other and bound by HOXD13. Silencing of HOXD13 reduces the contacts around the NT5E promoter. B, Bar dot plot representing CD73 protein quantification in tumor (left) and blood vessel (right) areas of a TMA in which cores were segregated into HOXD13 -expressing ( n = 61) and HOXD13 -negative ( n = 39). An unpaired t test was conducted, and P values are displayed. C, Representative HOXD13 low and HOXD13 high cores (RNAScope, top) and CD73, SOX10, and CD31/CD34 (mIF, bottom). The white scale bar measures 200 μm. D, qRT-PCR of Nt5e (Cd73) mRNA expression in B16F10 OVA cells that are EMPTY or Cd73 overexpressing, incubated with siSCR or siHoxd13. A paired t test was performed, and P values are shown in the graphs. E, Relative cell growth of B16F10 OVA carrying Cd73 ectopic expression cocultured with OT-I T cells upon Hoxd13 KD. A two-way ANOVA was conducted between the conditions. P values are shown. F, YUMM1.7 EMPTY or HOXD13 OE tumor growth expressing an shSCR (control) or shCd73. Mixed-effect analysis with Tukey comparison was conducted. The P value of the comparison YUMM1.7 HOXD13 shSCR vs. shCd73 is displayed. G, Tumor growth measurements of YUMM1.7 HOXD13 syngeneic grafts upon vehicle (control), lenvatinib, etrumadenant, or lenvatinib + etrumadenant (combo). Mixed-effects analysis through Tukey multiple comparison was performed, and P values are shown in the curves’ graph. H, Representative mIF staining for DAPI, CD45, CD3, CD11b, CD31, and α-SMA in YUMM1.7 HOXD13 tumors upon vehicle, etrumadenant, lenvatinib, and combo treatments. Combo dramatically decreased intratumor vasculature (CD31, α-SMA) and increased immune cells, particularly macrophage infiltration (CD45, CD11b). White bars reflect 500 mm size. I, B16F10 tumor growth in syngeneic mice upon shNTC, shHoxd13, or treated with vehicle or combo ( n = 9 mice per condition). Mixed-effect Tukey comparison was used as a statistical study; P values are shown. J, mIF opal staining for fibrin, α-SMA, and CD31 in representative tumor areas of B16F10 tumors shNTC, shHoxd13, vehicle, and combo treated. The scale bar is a reference of 50 μm.
    Figure Legend Snippet: CD73 is a key mediator of the HOXD13-dependent T-cell exclusion phenotype. A, The NT5E locus displays different regulatory elements contacting each other and bound by HOXD13. Silencing of HOXD13 reduces the contacts around the NT5E promoter. B, Bar dot plot representing CD73 protein quantification in tumor (left) and blood vessel (right) areas of a TMA in which cores were segregated into HOXD13 -expressing ( n = 61) and HOXD13 -negative ( n = 39). An unpaired t test was conducted, and P values are displayed. C, Representative HOXD13 low and HOXD13 high cores (RNAScope, top) and CD73, SOX10, and CD31/CD34 (mIF, bottom). The white scale bar measures 200 μm. D, qRT-PCR of Nt5e (Cd73) mRNA expression in B16F10 OVA cells that are EMPTY or Cd73 overexpressing, incubated with siSCR or siHoxd13. A paired t test was performed, and P values are shown in the graphs. E, Relative cell growth of B16F10 OVA carrying Cd73 ectopic expression cocultured with OT-I T cells upon Hoxd13 KD. A two-way ANOVA was conducted between the conditions. P values are shown. F, YUMM1.7 EMPTY or HOXD13 OE tumor growth expressing an shSCR (control) or shCd73. Mixed-effect analysis with Tukey comparison was conducted. The P value of the comparison YUMM1.7 HOXD13 shSCR vs. shCd73 is displayed. G, Tumor growth measurements of YUMM1.7 HOXD13 syngeneic grafts upon vehicle (control), lenvatinib, etrumadenant, or lenvatinib + etrumadenant (combo). Mixed-effects analysis through Tukey multiple comparison was performed, and P values are shown in the curves’ graph. H, Representative mIF staining for DAPI, CD45, CD3, CD11b, CD31, and α-SMA in YUMM1.7 HOXD13 tumors upon vehicle, etrumadenant, lenvatinib, and combo treatments. Combo dramatically decreased intratumor vasculature (CD31, α-SMA) and increased immune cells, particularly macrophage infiltration (CD45, CD11b). White bars reflect 500 mm size. I, B16F10 tumor growth in syngeneic mice upon shNTC, shHoxd13, or treated with vehicle or combo ( n = 9 mice per condition). Mixed-effect Tukey comparison was used as a statistical study; P values are shown. J, mIF opal staining for fibrin, α-SMA, and CD31 in representative tumor areas of B16F10 tumors shNTC, shHoxd13, vehicle, and combo treated. The scale bar is a reference of 50 μm.

    Techniques Used: Expressing, RNAscope, Quantitative RT-PCR, Incubation, Control, Comparison, Staining

    Related Articles

    Injection:

    Article Title: A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma
    Article Snippet: For the tumor growth assay, 1 × 10 5 A375, SKMEL-5, YUMM1.7, B16F10, and D4M-3A cells were injected intradermally in the flanks of 8-week-old male mice NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG; A375, SKMEL-5, and YUMM1.7) or C57BL/6J (YUMM1.7, D4M-3A, B16F10; The Jackson Laboratory) in a mix of 50% PBS + 50% Matrigel (Corning, 354234). .. For the etrumadenant and lenvatinib experiment, 8-week-old male mice C57BL/6J ( n = 10 per group) were injected intradermally in the flanks with 1 × 10 5 YUMM1.7 HOXD13 or B16F10, and after 3 days of grafting, mice were daily administered by oral gavage with 10 μg/g of lenvatinib (MedChemExpress, HY-10981) and/or 100 μg/g etrumadenant (MedChemExpress, HY-129393) or vehicle (95% corn oil + 5% DMSO). ..

    Article Title: A targetable developmental program co-regulates angiogenesis and immune evasion in melanoma
    Article Snippet: 868 Mouse experiments: 869 For tumor growth assay, 1x105 A375, SKMEL-5, YUMM1.7, B16F10 and D4M-3A cells were 870 injected intradermally in the flanks of 8 weeks old male mice NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 871 (NSG) (A375, SKMEL-5 and YUMM1.7) or C57BL/6J (YUMM1.7, D4M-3A, B16F10) (The 872 Jackson Laboratory) in a mix of 50% PBS + 50% Matrigel (Corning, 354234). .. For the 873 Etrumadenant and Lenvatinib experiment, 8 weeks old male mice C57BL/6J (n=10 per group) 874 were injected intradermally in the flanks with 1x105 YUMM1.7 HOXD13 or B16F10 and after 3 875 days of grafting, mice were daily administrated by oral gavage with 10g/gr of Lenvatinib 876 (MedChem Express, HY-10981) and/or 100g/gr Etrumadenant (MedChem Express, HY-877 129393) or vehicle (95% corn oil + 5% DMSO). ..

    Article Title: A targetable developmental program co-regulates angiogenesis and immune evasion
    Article Snippet: For tumor growth assay, 1×10 5 A375, SKMEL-5, YUMM1.7, B16F10 and D4M-3A cells were injected intradermally in the flanks of 8 weeks old male mice NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) (A375, SKMEL-5 and YUMM1.7) or C57BL/6J (YUMM1.7, D4M-3A, B16F10) (The Jackson Laboratory) in a mix of 50% PBS + 50% Matrigel (Corning, 354234). .. For the Etrumadenant and Lenvatinib experiment, 8 weeks old male mice C57BL/6J (n=10 per group) were injected intradermally in the flanks with YUMM1.7 HOXD13 and after 3 days of grafting, mice were daily administrated by oral gavage with 10ug/gr of Lenvatinib (MedChem Express, HY-10981) and/or Etrumadenant (MedChem Express, HY-129393) or vehicle (95% corn oil + 5% DMSO). ..



    Similar Products

    lenvatinib experiment  (MedChemExpress)
    97
    MedChemExpress lenvatinib experiment
    CD73 is a key mediator of the HOXD13-dependent T-cell exclusion phenotype. A, The NT5E locus displays different regulatory elements contacting each other and bound by HOXD13. Silencing of HOXD13 reduces the contacts around the NT5E promoter. B, Bar dot plot representing CD73 protein quantification in tumor (left) and blood vessel (right) areas of a TMA in which cores were segregated into HOXD13 -expressing ( n = 61) and HOXD13 -negative ( n = 39). An unpaired t test was conducted, and P values are displayed. C, Representative HOXD13 low and HOXD13 high cores (RNAScope, top) and CD73, SOX10, and CD31/CD34 (mIF, bottom). The white scale bar measures 200 μm. D, qRT-PCR of Nt5e (Cd73) mRNA expression in B16F10 OVA cells that are EMPTY or Cd73 overexpressing, incubated with siSCR or siHoxd13. A paired t test was performed, and P values are shown in the graphs. E, Relative cell growth of B16F10 OVA carrying Cd73 ectopic expression cocultured with OT-I T cells upon Hoxd13 KD. A two-way ANOVA was conducted between the conditions. P values are shown. F, YUMM1.7 EMPTY or HOXD13 OE tumor growth expressing an shSCR (control) or shCd73. Mixed-effect analysis with Tukey comparison was conducted. The P value of the comparison YUMM1.7 HOXD13 shSCR vs. shCd73 is displayed. G, Tumor growth measurements of YUMM1.7 HOXD13 syngeneic grafts upon vehicle (control), <t>lenvatinib,</t> etrumadenant, or lenvatinib + etrumadenant (combo). Mixed-effects analysis through Tukey multiple comparison was performed, and P values are shown in the curves’ graph. H, Representative mIF staining for DAPI, CD45, CD3, CD11b, CD31, and α-SMA in YUMM1.7 HOXD13 tumors upon vehicle, etrumadenant, lenvatinib, and combo treatments. Combo dramatically decreased intratumor vasculature (CD31, α-SMA) and increased immune cells, particularly macrophage infiltration (CD45, CD11b). White bars reflect 500 mm size. I, B16F10 tumor growth in syngeneic mice upon shNTC, shHoxd13, or treated with vehicle or combo ( n = 9 mice per condition). Mixed-effect Tukey comparison was used as a statistical study; P values are shown. J, mIF opal staining for fibrin, α-SMA, and CD31 in representative tumor areas of B16F10 tumors shNTC, shHoxd13, vehicle, and combo treated. The scale bar is a reference of 50 μm.
    Lenvatinib Experiment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lenvatinib+experiment/Lenvatinib/pmc13223554-372-4-49
    Average 97 stars, based on 1 article reviews
    lenvatinib experiment - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    CD73 is a key mediator of the HOXD13-dependent T-cell exclusion phenotype. A, The NT5E locus displays different regulatory elements contacting each other and bound by HOXD13. Silencing of HOXD13 reduces the contacts around the NT5E promoter. B, Bar dot plot representing CD73 protein quantification in tumor (left) and blood vessel (right) areas of a TMA in which cores were segregated into HOXD13 -expressing ( n = 61) and HOXD13 -negative ( n = 39). An unpaired t test was conducted, and P values are displayed. C, Representative HOXD13 low and HOXD13 high cores (RNAScope, top) and CD73, SOX10, and CD31/CD34 (mIF, bottom). The white scale bar measures 200 μm. D, qRT-PCR of Nt5e (Cd73) mRNA expression in B16F10 OVA cells that are EMPTY or Cd73 overexpressing, incubated with siSCR or siHoxd13. A paired t test was performed, and P values are shown in the graphs. E, Relative cell growth of B16F10 OVA carrying Cd73 ectopic expression cocultured with OT-I T cells upon Hoxd13 KD. A two-way ANOVA was conducted between the conditions. P values are shown. F, YUMM1.7 EMPTY or HOXD13 OE tumor growth expressing an shSCR (control) or shCd73. Mixed-effect analysis with Tukey comparison was conducted. The P value of the comparison YUMM1.7 HOXD13 shSCR vs. shCd73 is displayed. G, Tumor growth measurements of YUMM1.7 HOXD13 syngeneic grafts upon vehicle (control), lenvatinib, etrumadenant, or lenvatinib + etrumadenant (combo). Mixed-effects analysis through Tukey multiple comparison was performed, and P values are shown in the curves’ graph. H, Representative mIF staining for DAPI, CD45, CD3, CD11b, CD31, and α-SMA in YUMM1.7 HOXD13 tumors upon vehicle, etrumadenant, lenvatinib, and combo treatments. Combo dramatically decreased intratumor vasculature (CD31, α-SMA) and increased immune cells, particularly macrophage infiltration (CD45, CD11b). White bars reflect 500 mm size. I, B16F10 tumor growth in syngeneic mice upon shNTC, shHoxd13, or treated with vehicle or combo ( n = 9 mice per condition). Mixed-effect Tukey comparison was used as a statistical study; P values are shown. J, mIF opal staining for fibrin, α-SMA, and CD31 in representative tumor areas of B16F10 tumors shNTC, shHoxd13, vehicle, and combo treated. The scale bar is a reference of 50 μm.

    Journal: Cancer Discovery

    Article Title: A Targetable Developmental Program Coregulates Angiogenesis and Immune Evasion in Melanoma

    doi: 10.1158/2159-8290.CD-24-1853

    Figure Lengend Snippet: CD73 is a key mediator of the HOXD13-dependent T-cell exclusion phenotype. A, The NT5E locus displays different regulatory elements contacting each other and bound by HOXD13. Silencing of HOXD13 reduces the contacts around the NT5E promoter. B, Bar dot plot representing CD73 protein quantification in tumor (left) and blood vessel (right) areas of a TMA in which cores were segregated into HOXD13 -expressing ( n = 61) and HOXD13 -negative ( n = 39). An unpaired t test was conducted, and P values are displayed. C, Representative HOXD13 low and HOXD13 high cores (RNAScope, top) and CD73, SOX10, and CD31/CD34 (mIF, bottom). The white scale bar measures 200 μm. D, qRT-PCR of Nt5e (Cd73) mRNA expression in B16F10 OVA cells that are EMPTY or Cd73 overexpressing, incubated with siSCR or siHoxd13. A paired t test was performed, and P values are shown in the graphs. E, Relative cell growth of B16F10 OVA carrying Cd73 ectopic expression cocultured with OT-I T cells upon Hoxd13 KD. A two-way ANOVA was conducted between the conditions. P values are shown. F, YUMM1.7 EMPTY or HOXD13 OE tumor growth expressing an shSCR (control) or shCd73. Mixed-effect analysis with Tukey comparison was conducted. The P value of the comparison YUMM1.7 HOXD13 shSCR vs. shCd73 is displayed. G, Tumor growth measurements of YUMM1.7 HOXD13 syngeneic grafts upon vehicle (control), lenvatinib, etrumadenant, or lenvatinib + etrumadenant (combo). Mixed-effects analysis through Tukey multiple comparison was performed, and P values are shown in the curves’ graph. H, Representative mIF staining for DAPI, CD45, CD3, CD11b, CD31, and α-SMA in YUMM1.7 HOXD13 tumors upon vehicle, etrumadenant, lenvatinib, and combo treatments. Combo dramatically decreased intratumor vasculature (CD31, α-SMA) and increased immune cells, particularly macrophage infiltration (CD45, CD11b). White bars reflect 500 mm size. I, B16F10 tumor growth in syngeneic mice upon shNTC, shHoxd13, or treated with vehicle or combo ( n = 9 mice per condition). Mixed-effect Tukey comparison was used as a statistical study; P values are shown. J, mIF opal staining for fibrin, α-SMA, and CD31 in representative tumor areas of B16F10 tumors shNTC, shHoxd13, vehicle, and combo treated. The scale bar is a reference of 50 μm.

    Article Snippet: For the etrumadenant and lenvatinib experiment, 8-week-old male mice C57BL/6J ( n = 10 per group) were injected intradermally in the flanks with 1 × 10 5 YUMM1.7 HOXD13 or B16F10, and after 3 days of grafting, mice were daily administered by oral gavage with 10 μg/g of lenvatinib (MedChemExpress, HY-10981) and/or 100 μg/g etrumadenant (MedChemExpress, HY-129393) or vehicle (95% corn oil + 5% DMSO).

    Techniques: Expressing, RNAscope, Quantitative RT-PCR, Incubation, Control, Comparison, Staining